What FTC's 'Killer Acquisition' Theory Means For Pharma Cos.
By Joshua Goodman, Luisa Di Lauro and Zachary Johns · March 7, 2024, 6:46 PM EST
The Federal Trade Commission recently filed a lawsuit seeking to block Sanofi's acquisition of a proposed exclusive license to a pharmaceutical treatment still under development by Maze Therapeutics Inc., which led...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login